Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Suzanne Cain, Jennifer L. McQuade, Sapna Pradyuman Patel, Agop Y. Bedikian, Michael A. Davies, Srisuda Lecagoonporn, Roland L. Bassett, Patrick Hwu, Wen-Jen Hwu, Rodabe N. Amaria, Liberty Posada
Publikováno v:
Melanoma Research. 26:604-608
TPI 287 is a synthetic taxane derivative with structural modifications allowing for central nervous system penetration and potential circumvention of multidrug resistance efflux pump mechanisms. The aim of this phase I study was to determine the maxi
Autor:
Fa-Chyi Lee, Claire F. Verschraegen, Valerie Parks, Ian Rabinowitz, Sujana Movva, Aroop Mangalik
Publikováno v:
Melanoma research. 21(1)
This phase I study was carried out to evaluate the optimal dose of temozolomide in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Patients with advanced melanoma or small cell lung cancer that could benefit from t
Autor:
Gérard Guillet, Bernard Guillot, Bruno Sassolas, Jean Marc Tourani, Laurent Mourey, Christophe Bedane, E. Wierzbicka-Hainaut
Publikováno v:
Melanoma research. 20(2)
Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma. The purpose of this study was to test the efficacy and safety of combination therapy with TMZ and cisplatin (CDDP) in patients with
Autor:
Johan Hansson, Eva Månsson-Brahme, Bo Nilsson, Gunnar Wagenius, Boel Ragnarsson-Olding, Giuseppe Masucci
Publikováno v:
Karolinska Institutet
Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration. Previous clinical trials suggested that temozolomide in sequence with low-dose recombinant human interleukin-2 might be an efficaciou
Autor:
Julio Rifà, Elena Filipovich, J. R. Germa-Lluch, Xavier Garcia del Muro, Margarita García, X. Perez, Manuel Valladares, Carmen Crespo, Alejandro Tres, Juan José López
Publikováno v:
Melanoma research. 16(4)
OBJECTIVE Temozolomide is a novel oral alkylating agent, active against metastatic melanoma. Combinations of chemotherapy and biological response modifiers have been associated with increased antitumour activity. A multicentre phase II study was perf
Autor:
Tamar Safra, Ilan G. Ron, Einat Even Sapir, David Sarid, Moshe Inbar, Noam Asna, Shlomo Schneebaum, Ur Metser, Larisa Ryvo
Publikováno v:
Melanoma research. 16(1)
Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases. Twenty-three patients with advanced ino
Autor:
Marcelo Sánchez, Susana Puig, Joseph Malvehy, Marta Martin, Pere Gascón, Begoña Mellado, Rosa M. Martí, Teresa Castel, Joseph Herrero, María González Cao, Cristina Carrera, Carlos Conill
Publikováno v:
Melanoma research. 16(1)
The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma. Treatment consisted of temozolomide (150 mg/m per
Publikováno v:
Melanoma research. 15(6)
The present study was designed to assess the efficacy and safety of combination therapy with temozolomide plus cisplatin in patients with metastatic melanoma. Thirty patients with metastatic melanoma were enrolled. Treatment consisted of intravenous
Autor:
Kevin B. Kim, Mandy S Harting
Publikováno v:
Melanoma research. 14(6)
Patients with advanced vulvovaginal mucosal melanoma generally have a dismal prognosis, and no effective systemic therapy for the disease has been reported. The objective of this retrospective clinical study was to assess the clinical benefit of bioc